GlassScriptPhysician profile
Suresh Ramamurthy
NPI 1730358953
$4,136.83
in general payments reported to CMS, 2019-2025
29 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $248 · 2021: $544 · 2022: $493 · 2023: $705 · 2024: $603 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $651.10 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $513.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.65 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $380.11 | 2019-2022 | |
| Pfizer INC. | $317.84 | 2019-2025 | |
| Abbott Laboratories | $263.56 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Medtronic, INC. | $257.55 | 2024 | Symplicity G3, Selectsecure |
| Boston Scientific Corporation | $227.99 | 2019-2025 | General - Therapies, Watchman Flx, Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $209.39 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $144.34 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $133.65 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $80.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.07 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $65.84 | 2019-2023 | |
| Biotronik INC. | $57.84 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $45.47 | 2020 | |
| W. L. Gore & Associates, INC. | $39.84 | 2019-2021 | |
| Abiomed | $25.20 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $24.60 | 2024 | Arcalyst |
| Recor Medical INC | $24.25 | 2025 | Paradise Ultrasound Renal Denervation System |
| Daiichi Sankyo INC. | $22.50 | 2023 | Injectafer |
| Celgene Corporation | $20.89 | 2024 | Camzyos |
| Siemens Medical Solutions USA, INC. | $19.81 | 2022 | |
| Portola Pharmaceuticals, LLC | $18.80 | 2019 | |
| Cardiva Medical, INC. | $18.30 | 2021 | |
| Cvrx, INC. | $17.73 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.46 | 2023 | Opsumit, Uptravi |
| Chiesi USA, INC. | $14.54 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Ramamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.